• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.在制造过程中简化嵌合抗原受体 T 细胞浓度、大小、活力和双色表型的测量。
Cytotherapy. 2024 May;26(5):506-511. doi: 10.1016/j.jcyt.2024.01.007. Epub 2024 Feb 16.
2
Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.在学术医学中心使用 CliniMACS Prodigy 设备进行封闭式制造 CD19 和双靶点 CD20/19 嵌合抗原受体 T 细胞。
Cytotherapy. 2018 Mar;20(3):394-406. doi: 10.1016/j.jcyt.2017.09.005. Epub 2017 Dec 26.
3
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications.用于CAR-T细胞应用免疫监测的先进流式细胞术检测
Front Immunol. 2021 May 3;12:658314. doi: 10.3389/fimmu.2021.658314. eCollection 2021.
4
Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry.基于图像的细胞术分析 CAR T 细胞在体外生产过程中的扩增和细胞毒性潜能。
J Immunol Methods. 2020 Sep-Oct;484-485:112830. doi: 10.1016/j.jim.2020.112830. Epub 2020 Aug 1.
5
Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.在床边使用 CliniMACS Prodigy 系统对抗 CD19 CAR T 细胞产品进行扩展特征分析:供体来源和处理时间的比较。
Cytotherapy. 2024 Jun;26(6):567-578. doi: 10.1016/j.jcyt.2024.02.025. Epub 2024 Mar 2.
6
Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.通过静息步骤提高临床级嵌合抗原受体工程化 T 细胞的体外效力测定。
Cytotherapy. 2019 May;21(5):566-578. doi: 10.1016/j.jcyt.2019.02.013. Epub 2019 Mar 23.
7
T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function.T 细胞激活剂对嵌合抗原受体 T 细胞表型和功能表现出不同的下游效应。
Immunohorizons. 2024 Jun 1;8(6):404-414. doi: 10.4049/immunohorizons.2400008.
8
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.嵌合抗原受体 T 细胞疗法治疗小儿 B-ALL:缩小早期和长期结局之间的差距。
Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.
9
Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19 hematologic indications.开发针对 CD19 血液肿瘤适应证的利妥昔单抗注射液嵌合抗原受体 T 细胞的生产工艺,以改善工艺、产品质量和一致性。
Cytotherapy. 2022 Sep;24(9):962-973. doi: 10.1016/j.jcyt.2022.03.013. Epub 2022 May 21.
10
Basic Procedures for Detection and Cytotoxicity of Chimeric Antigen Receptors.嵌合抗原受体的检测及细胞毒性的基本程序
Methods Mol Biol. 2019;1904:299-306. doi: 10.1007/978-1-4939-8958-4_13.

本文引用的文献

1
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.血液恶性肿瘤中嵌合抗原受体 T 细胞耐药的机制。
Nat Rev Drug Discov. 2023 Dec;22(12):976-995. doi: 10.1038/s41573-023-00807-1. Epub 2023 Oct 31.
2
Potential solutions for manufacture of CAR T cells in cancer immunotherapy.癌症免疫治疗中 CAR T 细胞制造的潜在解决方案。
Nat Commun. 2022 Sep 5;13(1):5225. doi: 10.1038/s41467-022-32866-0.
3
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.调节 T 细胞和肿瘤细胞中的 BCL-2 以增强嵌合抗原受体 T 细胞免疫疗法治疗癌症。
Cancer Discov. 2022 Oct 5;12(10):2372-2391. doi: 10.1158/2159-8290.CD-21-1026.
4
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.白细胞分离术指导与嵌合抗原受体 T 细胞最优生产的最佳实践
Cytotherapy. 2022 Sep;24(9):869-878. doi: 10.1016/j.jcyt.2022.05.003. Epub 2022 Jun 17.
5
Impact of Manufacturing Procedures on CAR T Cell Functionality.制造工艺对 CAR T 细胞功能的影响。
Front Immunol. 2022 Apr 13;13:876339. doi: 10.3389/fimmu.2022.876339. eCollection 2022.
6
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.阿基仑赛注射液治疗复发或难治性惰性非霍奇金淋巴瘤(ZUMA-5):一项单臂、多中心、2 期临床试验。
Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8.
7
The Coulter Principle: A history.库尔特原理:一部历史
Cytometry A. 2022 Jan;101(1):8-11. doi: 10.1002/cyto.a.24505. Epub 2021 Oct 6.
8
Engineering enhanced CAR T-cells for improved cancer therapy.工程改造增强型嵌合抗原受体T细胞以改善癌症治疗。
Nat Cancer. 2021 Aug;2(8):780-793. doi: 10.1038/s43018-021-00241-5. Epub 2021 Aug 19.
9
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛,一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法,用于治疗复发或难治性多发性骨髓瘤患者(CARTITUDE-1):一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
10
Idecabtagene Vicleucel in Relapsed Myeloma. Reply.伊德卡替宁-维克利尤单抗治疗复发型骨髓瘤。回复。
N Engl J Med. 2021 Jun 17;384(24):2357-2358. doi: 10.1056/NEJMc2105069.

在制造过程中简化嵌合抗原受体 T 细胞浓度、大小、活力和双色表型的测量。

Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.

机构信息

Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

出版信息

Cytotherapy. 2024 May;26(5):506-511. doi: 10.1016/j.jcyt.2024.01.007. Epub 2024 Feb 16.

DOI:10.1016/j.jcyt.2024.01.007
PMID:38483365
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11259153/
Abstract

BACKGROUND AIMS

The successful development of CD19-targeted chimeric antigen receptor (CAR) T-cell therapies has led to an exponential increase in the number of patients recieving treatment and the advancement of novel CAR T products. Therefore, there is a strong need to develop streamlined platforms that allow rapid, cost-effective, and accurate measurement of the key characteristics of CAR T cells during manufacturing (i.e., cell number, cell size, viability, and basic phenotype).

METHODS

In this study, we compared the novel benchtop cell analyzer Moxi GO II (ORFLO Technologies), which enables simultaneous evaluation of all the aforementioned parameters, with current gold standards in the field: the Multisizer Coulter Counter (cell counter) and the BD LSRFortessa (flow cytometer).

RESULTS

Our results demonstrated that the Moxi GO II can accurately measure cell number and cell size (i.e., cell volume) while simultaneously assessing simple two-color flow cytometry parameters, such as CAR T-cell viability and CD4 or CAR expression.

CONCLUSIONS

These measurements are comparable with those of gold standard instruments, demonstrating that the Moxi GO II is a promising platform for quickly monitoring CAR T-cell growth and phenotype in research-grade and clinical samples.

摘要

背景目的

成功开发了针对 CD19 的嵌合抗原受体(CAR)T 细胞疗法,使得接受治疗的患者数量呈指数级增长,并且新型 CAR T 产品也不断涌现。因此,强烈需要开发简化的平台,以便在制造过程中(即细胞数量、细胞大小、活力和基本表型)快速、经济高效且准确地测量 CAR T 细胞的关键特征。

方法

在这项研究中,我们将新型台式细胞分析仪 Moxi GO II(ORFLO Technologies)与该领域的当前金标准进行了比较:Multisizer Coulter 计数器(细胞计数器)和 BD LSRFortessa(流式细胞仪)。

结果

我们的结果表明,Moxi GO II 可以准确测量细胞数量和细胞大小(即细胞体积),同时还可以评估简单的双色流式细胞术参数,如 CAR T 细胞活力和 CD4 或 CAR 表达。

结论

这些测量结果与金标准仪器相当,表明 Moxi GO II 是一种有前途的平台,可用于快速监测研究级和临床样本中 CAR T 细胞的生长和表型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9349/11259153/806611c856e8/nihms-1993666-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9349/11259153/4d182e2e698e/nihms-1993666-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9349/11259153/fe4ddb5f5752/nihms-1993666-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9349/11259153/806611c856e8/nihms-1993666-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9349/11259153/4d182e2e698e/nihms-1993666-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9349/11259153/fe4ddb5f5752/nihms-1993666-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9349/11259153/806611c856e8/nihms-1993666-f0003.jpg